https://pentraxin.wordpress.com/
The company designs new treatments for systemic amyloidosis and the amyloid-related diseases, Alzheimer’s disease and type II diabetes, as well as targeting the pathogenic effects of C-reactive protein in cardiovascular and inflammatory diseases.